Phage-Derived Oncolytic Viruses with 3C from Seneca Valley Virus for Targeted Therapy of Cervical Cancer
Advanced Therapeutics
; 5(8), 2022.
Article
in English
| EMBASE | ID: covidwho-2007088
ABSTRACT
Cancer gene therapy based on various gene delivery vectors has some potential but also has obvious disadvantages. In this study, a new M13 phage-based oncolytic virus is constructed that carried the RGD peptides to target tumor cells and the 3C gene of Seneca Valley virus (SVV) preceded by a eukaryotic initial transcriptional region (ITR) to transcribe an oncolytic protein to kill tumor cells. Recombinant virus particles of 1200 nm in length are obtained in large quantities by transfecting the recombinant M13 phage plasmid into the host BL2738 and are investigated in vitro in tumor cells and in vivo in tumor-bearing mice to evaluate their antitumor effect. The experiments using Hela cells confirm that the engineered M13 phage can target and enter Hela cells, and express the SVV 3C protein, resulting in apoptosis of target cells by upregulating the expression of caspase 3. Furthermore, the results of experiments in vivo also show that the recombinant phage significantly inhibits the enhanced tumor volume in nude mice compared to the control groups. The M13 phage may be engineered to fuse with a variety of oncolytic proteins to inhibit the growth of tumor cells in the future, providing a promising phage-based targeted oncolytic reagent.
alphaVbeta5 integrin; arginylglycylaspartic acid; caspase 3; coronavirus 3C protease; messenger RNA; oncolytic virus; vitronectin receptor; animal experiment; animal model; animal tissue; antineoplastic activity; apoptosis; article; cancer gene therapy; cell activity; cell proliferation; controlled study; Enterobacteria phage M13; enzyme activity; female; flow cytometry; gene expression regulation; genetic transcription; HeLa cell line; homologous recombination; host; host cell; human; human cell; in vitro study; in vivo study; initial transcriptional region; large scale production; mouse; mRNA expression level; nonhuman; oncolytic virotherapy; phage therapy; pharmacokinetic parameters; plasmid; Seneca valley virus; Senecavirus; target cell; transmission electron microscopy; tumor regression; tumor volume; tumor xenograft; upregulation; uterine cervix cancer; viral gene delivery system; virus gene; virus genome; virus particle; virus recombinant
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Advanced Therapeutics
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS